Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma

作者全名："Wei, Xiaojing; Wang, Xiaodong; Xiong, Jie; Li, Chen; Liao, Yixuan; Zhu, Yongjun; Mao, Jingxin"

作者地址："[Wei, Xiaojing] Chongqing Jiaotong Univ Hosp, Chongqing 400074, Peoples R China; [Wang, Xiaodong; Mao, Jingxin] Chongqing Med & Pharmaceut Coll, Chongqing 400030, Peoples R China; [Xiong, Jie] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Dept Pharm, Minist Educ,Key Lab Child Dev & Disorders,Children, Chongqing 400014, Peoples R China; [Li, Chen] Free Univ Berlin, Dept Biol, Pharm, Chem, D-14195 Berlin, Germany; [Liao, Yixuan; Mao, Jingxin] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400715, Peoples R China; [Zhu, Yongjun] Ninth Peoples Hosp Chongqing, Orthoped Dept, Chongqing 400700, Peoples R China"

通信作者："Mao, JX (通讯作者)，Chongqing Med & Pharmaceut Coll, Chongqing 400030, Peoples R China.; Mao, JX (通讯作者)，Southwest Univ, Coll Pharmaceut Sci, Chongqing 400715, Peoples R China.; Zhu, YJ (通讯作者)，Ninth Peoples Hosp Chongqing, Orthoped Dept, Chongqing 400700, Peoples R China."

来源：BIOMED RESEARCH INTERNATIONAL

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000806025400006

JCR分区：Q3

影响因子：3.246

年份：2022

卷号：2022

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：　

摘要："Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC) worldwide has been increasing rapidly year by year, with the incidence rate increasing 6% annually. PTC has become the malignant tumor with the highest growth rate in the world that fourteen PTC-related mutant genes have been identified. Whether the BRAFV600E mutation related to more aggressive clinicopathologic features and worse outcome in PTC remains variable and controversial. We aim to investigate the risk factors that may predict the BRAFV600E mutation potential of these lesions and new prevention strategies in PTC patients. Methods. A total of 9,908 papillary thyroid carcinoma patients with average 74.6% BRAFV600E mutations were analyzed (RevMan 5.3 software) in this study. The PubMed, Embase, and ISI Web of Science databases were systematically searched for works published through December 15, 2021. Results. The following variables were associated with an increased risk of BRAFV600E mutation in PTC patients: age >= 45 years (OR = 1.39, 95%CI = 1.21 - 1.60, p < 0.00001), male gender (OR = 1.13, 95%CI = 0.99 - 1.28, p = 0.06), multifocality (OR = 1.22, 95%CI = 1.07 - 1.40, p = 0.004), lymph node metastasis (OR = 1.33, 95%CI = 0.79 - 2.23, p = 0.28), extrathyroidal extension + (OR = 1.61, 95%CI = 1.06 - 2.44, p = 0.03), vascular invasion + (OR = 2.04, 95%CI = 1.32 - 3.15, p = 0.001), and tumor node metastasis stage (OR = 1.61, 95%CI = 1.38 - 1.88, p < 0.00001). In addition, tumor size (> 1 cm) (OR = 0.51, 95%CI = 0.32 - 0.81, p = 0.005) and distant metastasis (OR = 0.69, 95% CI = 0.22 - 2.21, p = 0.54) had no association or risk with BRAF(V600E )mutation in PTC patients. Conclusion. Our systematic review identified the following significant risk factors of BRAF(V600E) mutation in PTC patients: age (>= 45 years), gender (male), multifocality, lymph node metastasis, vascular invasion, extrathyroidal extension, and advanced tumor node metastasis stage (stages III and IV). Tumor size (> 1 cm) and distant metastasis do not appear to be correlated with BRAFV600E mutation in PTC patients."

基金机构：2020 Ministerial Project of China [2020YYCXCQSJ050]

基金资助正文：This work was supported by 2020 Ministerial Project of China (No. 2020YYCXCQSJ050).